v3.25.1

Discontinued operations and assets held for sale - Transfer of Jyseleca Business to Alfasigma (Details) - Jyseleca business, classified as held for sale |  |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Jan. 31, 2024 EUR (€) position country | Dec. 30, 2023 item | Oct. 30, 2023 country | Jan. 31, 2024 EUR (€) item country | Dec. 31, 2024 EUR (€)
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Number of positions in European countries agreed to transfer | 400 | 400 |  | 400 |
Number of European countries in which positions has been agreed to transfer | country | 14 |  | 14 | 14 |
Upfront payment to receive. |  |  |  | € 50,000,000 | € 50,000,000
Potential Sales Based Milestones To Receive. | € 120,000,000 |  |  | € 120,000,000 | 120,000,000
Commitments Related To Development Activities. |  |  |  |  | 25,000,000
Contributions related to development activities. |  |  |  |  | € 15,000,000
Galapagos Biotech Ltd. (formerly Inpharmatica Ltd.) |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma Belgium BV [member] |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma Germany GmbH |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma Italy S.r.l. |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma Netherlands BV [member] |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma Spain S.L.U |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma ApS |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma A.B. |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma Oy |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos Biopharma Ireland Ltd |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%
Galapagos GmbH |  |  |  |  |
Disclosure of analysis of single amount of off-balance sheet arrangements [line items] |  |  |  |  |
Proportion Of Ownership Interest In Subsidiary Sold |  |  |  |  | 100.00%

X
- Definition Commitments to Alfasigma related to development activities. + References No definition available. + Details
Name: | glpg_CommitmentsRelatedToDevelopmentActivities.
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition contributions to Alfasigma related to development activities. + References No definition available. + Details
Name: | glpg_ContributionsToRelatedDevelopmentActivities.
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of European countries agreed in which positions has been agreed to transfer, pursuant to an arrangement. + References No definition available. + Details
Name: | glpg_NumberOfEuropeanCountriesInWhichPositionsHasBeenAgreedToTransfer
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of positions agreed to transfer, pursuant to an arrangement. + References No definition available. + Details
Name: | glpg_NumberOfPositionsAgreedToTransfer
Namespace Prefix: | glpg_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity that is sold. + References No definition available. + Details
Name: | glpg_ProportionOfOwnershipInterestInSubsidiarySold
Namespace Prefix: | glpg_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash inflow received as upfront payment. + References No definition available. + Details
Name: | glpg_UpfrontPaymentReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of upfront payments receivable. + References No definition available. + Details
Name: | glpg_UpfrontPaymentsReceivable
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ContinuingAndDiscontinuedOperationsAxis=glpg_JyselecaBusinessClassifiedAsHeldForSaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiotechLtd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaBelgiumBvMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaS.r.lMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaNetherlandsBvMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaS.l.uMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaApsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaA.b.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaOyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosBiopharmaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=glpg_GalapagosGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |